The polypill developed by CNIC and Ferrer contains three drugs (aspirin, angiotensin-converting enzyme (ACE) inhibitors and statins) that are effective in preventing A second adverse cardiovascular event in patients with a history of heart attack was associated with a 33% reduction in cardiovascular mortality in this population.

The SECURE study, led by the Spanish National Center for Cardiovascular Research (CNIC), came to this conclusion. The findings were presented today at the hotline session of the European Society of Cardiology meeting (ESC 2022) in Barcelona and published in the New England Journal of Medicine (NEJM) 1 .

Dr. Valentín Fuster, Principal Investigator of the SECURE study, Director General of CNIC, Director of the Department of Cardiology at Mount Sinai Hospital, and Attending Physician at Mount Sinai Hospital, said: "The results of the SECURE study show for the first time that polypill is effective in patients with heart disease. Clinically relevant recurrent cardiovascular events were reduced in patients with a history of exacerbations."

SECURE enrolled 2499 patients with a history of myocardial infarction from 7 European countries (Spain, Italy, Germany, Czech Republic, France, Poland and Hungary). Study participants were randomized to receive standard therapy or CNIC polypill * . The average age of the participants was 76 years, and 31 percent were women. 77.9% of the study population had hypertension, 57.4% had diabetes, and 51.3% had a history of smoking.

The SECURE trial analyzed the incidence of four major cardiovascular events: death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization (restoration of blood flow to blocked coronary arteries). The study followed patients for an average of 3 years and concluded that those taking polypill had a 24 percent lower risk of developing all four of these events than those taking all three drugs alone.

The study's most striking finding was that polypill affected the key outcome, cardiovascular-related death. The data showed a 33% reduction in relative mortality. Seventy-one patients in the standard-care group died from cardiovascular disease, compared with 48 in the polypill group.

The study also found that patients in the polypill group had higher treatment adherence than those in the control group, confirming findings from a previous FOCUS 2 study, also funded by the EU.

Oscar Pérez, Chief Marketing, Market Access and Business Development Officer, Ferrer said: "The 33% reduction in cardiovascular mortality demonstrates the efficacy of Trinomia treatment compared to standard care. Our mission is to provide people with serious health conditions that make a difference. This achievement represents an important milestone in our commitment to achieving this mission.”

The SECURE trial was funded by the European Union's Horizon 2020 research and innovation programme (trial identifier NCT02596126).

• Polypill Strategy in Secondary Cardiovascular Prevention Castellano JM, Fuster V et al. New England Journal of Medicine (NEJM). 2022 Aug.
• Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014 Nov 18-25;64(20):2071-82

* Trinomia®, Sincronium®, Iltria® contain aspirin (100 mg), ACE inhibitor lamipril (2.5, 5 or 10 mg) and atorvastatin (20 or 40 mg).

Disclaimer: The original version of this announcement is the official authorized version. The translation is for convenience only. Please refer to the original text. The original version is the only legally binding version.

Contacts
For more information or contact for an interview:
Fátima Lois:

Head of Communications - CNIC.

flois@cnic.es

 639282477

Alba Soler:

Head of Communications - Ferrer.

asolerc@ferrer.com

699 904 180

 

Source:businesswire.com

Report Abuse